Biocon shares in focus after successful results of Yesintek in Phase 3
Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...
Managed Healthcare Executive12d
MedImpact Adds the Biosimilars Selarsdi and Yesintek to Formulary
Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...
Medical Dialogues3d
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics
Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...
CNBCTV184d
Biocon Biologics’ biosimilar Yesintek shows positive phase 3 results for psoriasis treatment
The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 ...
Yahoo Finance4d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara (Ustekinumab), marking a significant milestone for ...
Healio7d
First four Stelara biosimilars launch in US; ‘white labeling’ threatens market ‘vibrancy’
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...
Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...
Biocon share price up 2% as arm launches Yesintek in US; check details here
Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available to patients in US ...
Biocon share price in focus after arm launches product in US for autoimmune diseases
Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved for multiple conditions, this product aims to improve patient access to ...
Morningstar4d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
This Phase 3 study reaffirms the quality and therapeutic equivalence of YESINTEK compared to reference product, Stelara. The study demonstrated equivalent efficacy, safety, immunogenicity ...
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...